XML 34 R24.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 18 - Reportable Segments | 9 Months Ended
--- | ---
Sep. 30, 2024
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 18. Reportable Segments The Company has two reportable segments: (i) e-Commerce Operations, which involves acquiring and leasing, primarily an e-commerce platform to collaborate with businesses to optimize their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue, and other related businesses and (ii) Healthcare Operations, which provides third party administrator (TPA), data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, and health practice risk management. The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two business segments, the segments are managed separately because each requires different business strategies. The following tables present a summary of the reportable segments (in thousands):
For the Three Months Ended September 30, 2024 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 9,076 |  |  | $ | — |  |  | $ | 9,076 |
e-Commerce revenue |  |  | 3,834 |  |  |  | — |  |  |  | — |  |  |  | 3,834 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 2,457 |  |  |  | — |  |  |  | 2,457 |
Revenues, net |  | $ | 3,834 |  |  | $ | 11,533 |  |  | $ | — |  |  | $ | 15,367 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 2,756 |  |  |  | 9,091 |  |  |  | — |  |  |  | 11,847 |
Selling, general and administrative |  |  | 969 |  |  |  | 1,384 |  |  |  | (60 | ) |  |  | 2,293 |
Salaries, wages and payroll taxes |  |  | 617 |  |  |  | 2,258 |  |  |  | — |  |  |  | 2,875 |
Impairment loss |  |  | — |  |  |  | 3,729 |  |  |  | — |  |  |  | 3,729 |
Professional fees |  |  | 1,481 |  |  |  | 663 |  |  |  | — |  |  |  | 2,144 |
Depreciation and amortization |  |  | 141 |  |  |  | 337 |  |  |  | — |  |  |  | 478 |
Total expenses |  |  | 5,964 |  |  |  | 17,462 |  |  |  | (60 | ) |  |  | 23,366 |
Loss before other (income) expense |  |  | (2,130 | ) |  |  | (5,929 | ) |  |  | 60 |  |  |  | (7,999 | )
Other income |  |  | (324 | ) |  |  | (116 | ) |  |  | 60 |  |  |  | (380 | )
Loss before income taxes |  |  | (1,806 | ) |  |  | (5,813 | ) |  |  | — |  |  |  | (7,619 | )
Income taxes |  |  | (45 | ) |  |  | — |  |  |  | — |  |  |  | (45 | )
Net loss |  | $ | (1,851 | ) |  | $ | (5,813 | ) |  | $ | — |  |  | $ | (7,664 | )
For the Three Months Ended September 30, 2023 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 9,888 |  |  | $ | — |  |  | $ | 9,888 |
e-Commerce revenue |  |  | 2,931 |  |  |  | — |  |  |  | — |  |  |  | 2,931 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 2,471 |  |  |  | — |  |  |  | 2,471 |
Revenues, net |  | $ | 2,931 |  |  | $ | 12,359 |  |  | $ | — |  |  | $ | 15,290 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 2,127 |  |  |  | 8,578 |  |  |  | — |  |  |  | 10,705 |
Selling, general and administrative |  |  | 1,978 |  |  |  | 2,269 |  |  |  | (60 | ) |  |  | 4,187 |
Salaries, wages and payroll taxes |  |  | 564 |  |  |  | 1,919 |  |  |  | — |  |  |  | 2,483 |
Professional fees |  |  | 278 |  |  |  | 243 |  |  |  | — |  |  |  | 521 |
Depreciation and amortization |  |  | 164 |  |  |  | 707 |  |  |  | — |  |  |  | 871 |
Total expenses |  |  | 5,111 |  |  |  | 13,716 |  |  |  | (60 | ) |  |  | 18,767 |
Loss before other (income) expense |  |  | (2,180 | ) |  |  | (1,357 | ) |  |  | 60 |  |  |  | (3,477 | )
Other (income) expense |  |  | (76 | ) |  |  | 17 |  |  |  | 60 |  |  |  | 1 |
Loss before income taxes |  |  | (2,104 | ) |  |  | (1,374 | ) |  |  | — |  |  |  | (3,478 | )
Income taxes |  |  | (23 | ) |  |  | — |  |  |  | — |  |  |  | (23 | )
Loss before equity method investment |  |  | (2,127 | ) |  |  | (1,374 | ) |  |  | — |  |  |  | (3,501 | )
Gain on equity method investment |  |  | 6,138 |  |  |  | — |  |  |  | — |  |  |  | 6,138 |
Equity in net loss of affiliate |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Net loss |  | $ | 4,011 |  |  | $ | (1,374 | ) |  | $ | — |  |  | $ | 2,637 |
For the Nine Months Ended September 30, 2024 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 30,922 |  |  | $ | — |  |  | $ | 30,922 |
e-Commerce revenue |  |  | 10,210 |  |  |  | — |  |  |  | — |  |  |  | 10,210 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 8,717 |  |  |  | — |  |  |  | 8,717 |
Revenues, net |  | $ | 10,210 |  |  | $ | 39,639 |  |  | $ | — |  |  | $ | 49,849 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 7,217 |  |  |  | 28,496 |  |  |  | — |  |  |  | 35,713 |
Selling, general and administrative |  |  | 3,517 |  |  |  | 3,179 |  |  |  | (180 | ) |  |  | 6,516 |
Salaries, wages and payroll taxes |  |  | 1,744 |  |  |  | 6,540 |  |  |  | — |  |  |  | 8,284 |
Impairment loss |  |  | — |  |  |  | 13,653 |  |  |  | — |  |  |  | 13,653 |
Professional fees |  |  | 2,608 |  |  |  | 1,525 |  |  |  | — |  |  |  | 4,133 |
Depreciation and amortization |  |  | 417 |  |  |  | 1,870 |  |  |  | — |  |  |  | 2,287 |
Total expenses |  |  | 15,503 |  |  |  | 55,263 |  |  |  | (180 | ) |  |  | 70,586 |
Loss before other (income) expense |  |  | (5,293 | ) |  |  | (15,624 | ) |  |  | 180 |  |  |  | (20,737 | )
Other income |  |  | (735 | ) |  |  | (166 | ) |  |  | 180 |  |  |  | (721 | )
Loss before income taxes |  |  | (4,558 | ) |  |  | (15,458 | ) |  |  | — |  |  |  | (20,016 | )
Income taxes |  |  | (92 | ) |  |  | — |  |  |  | — |  |  |  | (92 | )
Net loss |  | $ | (4,650 | ) |  | $ | (15,458 | ) |  | $ | — |  |  | $ | (20,108 | )
For the Nine Months Ended September 30, 2023 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 9,888 |  |  | $ | — |  |  | $ | 9,888 |
e-Commerce revenue |  |  | 8,764 |  |  |  | — |  |  |  | — |  |  |  | 8,764 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 2,471 |  |  |  | — |  |  |  | 2,471 |
Revenues, net |  | $ | 8,764 |  |  | $ | 12,359 |  |  | $ | — |  |  | $ | 21,123 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 6,495 |  |  |  | 8,579 |  |  |  | — |  |  |  | 15,074 |
Selling, general and administrative |  |  | 5,287 |  |  |  | 2,269 |  |  |  | (60 | ) |  |  | 7,496 |
Salaries, wages and payroll taxes |  |  | 2,120 |  |  |  | 1,919 |  |  |  | — |  |  |  | 4,039 |
Professional fees |  |  | 1,143 |  |  |  | 242 |  |  |  | — |  |  |  | 1,385 |
Depreciation and amortization |  |  | 493 |  |  |  | 708 |  |  |  | — |  |  |  | 1,201 |
Total expenses |  |  | 15,538 |  |  |  | 13,717 |  |  |  | (60 | ) |  |  | 29,195 |
Loss before other (income) expense |  |  | (6,774 | ) |  |  | (1,358 | ) |  |  | 60 |  |  |  | (8,072 | )
Other (income) expense |  |  | (635 | ) |  |  | 17 |  |  |  | 60 |  |  |  | (558 | )
Loss before income taxes |  |  | (6,139 | ) |  |  | (1,375 | ) |  |  | — |  |  |  | (7,514 | )
Income taxes |  |  | (75 | ) |  |  | — |  |  |  | — |  |  |  | (75 | )
Loss before equity method investment |  |  | (6,214 | ) |  |  | (1,375 | ) |  |  | — |  |  |  | (7,589 | )
Gain on equity method investment |  |  | 6,138 |  |  |  | — |  |  |  | — |  |  |  | 6,138 |
Equity in net loss of affiliate |  |  | (1,440 | ) |  |  | — |  |  |  | — |  |  |  | (1,440 | )
Net loss |  | $ | (1,516 | ) |  | $ | (1,375 | ) |  | $ | — |  |  | $ | (2,891 | )
|  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Total assets as of September 30, 2024 |  | $ | 38,566 |  |  | $ | 19,212 |  |  | $ | (16,679 | ) |  | $ | 41,099 |
Total assets as of December 31, 2023 |  | $ | 40,764 |  |  | $ | 40,384 |  |  | $ | (16,679 | ) |  | $ | 64,469 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration